Figure 3From: Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinoneScatter plot comparing tedizolid and linezolid minimum inhibitory concentration (MIC) values for 1241 enterococcal isolates. Dashed lines represent the US Food and Drug Administration approved Enterococcus faecalis breakpoint for tedizolid generalized for all enterococci (≤0.5 μg/ml [susceptible]) and the Clinical and Laboratory Standards Institute approved breakpoints for linezolid (≤2 μg/ml [susceptible], 4 μg/ml [intermediate], and ≥8 μg/ml [resistant]).Back to article page